Forge Biologics Capacity Update February 2024: Cell & Gene

Forge’s Director of Client Development, Andrew Krajewski, highlights Forge’s 200,000 square foot, custom-designed cGMP facility dedicated to AAV and plasmid manufacturing. Forge’s end-to-end development and manufacturing capabilities include research-grade production, analytical and process development, toxicology, engineering, and cGMP manufacturing, automated and semi-automated fill-finish and stability, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.